Lenzetto (Estradiol)

Estradiol in Lenzetto binds to estrogen receptors (ERα and ERβ) inside cells, forming a complex that regulates the transcription of genes responsive to estrogen. This restores normal estrogenic activity in tissues, reducing vasomotor symptoms, improving urogenital health, and supporting bone metabolism.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the individual’s symptoms, health status, and response to therapy. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Lenzetto is not recommended for use during pregnancy because estradiol can affect fetal development. Safety during breastfeeding has not been established; therefore, it should be avoided unless the benefits outweigh potential risks and a healthcare provider advises otherwise.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenzetto delivers estradiol through the skin, offering more stable plasma levels than oral tablets, which undergo first‑pass metabolism. Compared with other transdermal patches, Lenzetto provides a convenient once‑weekly or twice‑weekly application schedule, but the exact frequency depends on the prescribed strength and patient response.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original foil pouch. Keep them away from direct sunlight, moisture, and heat sources. Do not freeze the patches, and discard any that appear damaged or discolored before use.

Lenzetto is applied to clean, dry, and hair‑free skin on the lower abdomen, buttock, or upper arm. The patch should be pressed firmly for several seconds to ensure adhesion. It is replaced according to the schedule prescribed by the clinician, typically every 3–7 days, and the previous patch should be removed and disposed of safely.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, cerebrovascular accidents (stroke), and myocardial infarction. Patients should be monitored for signs of blood clots, sudden severe headache, visual changes, or chest pain, and seek immediate medical attention if these occur.

Lenzetto is contraindicated in women with known or suspected estrogen‑dependent cancers (e.g., breast or endometrial carcinoma), active or past thromboembolic disease, unexplained vaginal bleeding, severe liver disease, or known hypersensitivity to estradiol or any patch components.